Keyphrases
Percutaneous Coronary Intervention
100%
Ticagrelor
63%
Cardiovascular Disease
62%
Confidence Interval
54%
Acute Coronary Syndrome
48%
Myocardial Infarction
44%
Revascularization
42%
Cardiovascular Risk
41%
Major Adverse Cardiovascular Events
39%
Atrial Fibrillation
37%
Cardiovascular Health
34%
Coronary Artery Disease
34%
Risk Factors
33%
Intervention Group
33%
Cardiovascular Mortality
32%
Type 2 Diabetes Mellitus (T2DM)
32%
Hazard Ratio
32%
Atherosclerotic Plaque
31%
Diabetic Patients
30%
Major Bleeding
29%
Clopidogrel
28%
Patients with Diabetes
28%
Secondary Prevention
27%
Prior Myocardial Infarction
27%
Multivessel Coronary Artery Disease
27%
Long-term Cardiovascular Outcomes
27%
Bleeding
26%
Placebo
26%
Cardiovascular Events
24%
Diabetes
23%
Plaque Burden
23%
Healthy Behaviors
22%
Clinical Outcomes
21%
Cardiovascular Health Promotion
21%
Type 2 Diabetic Patients
21%
Chronic Kidney Disease
20%
All-cause Mortality
20%
Health Promotion
20%
Lifestyle Intervention
20%
FDG Uptake
20%
Family-based Approaches
19%
Catheterization
19%
Triage Strategy
19%
Urgent Intervention
19%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
19%
Coronary Disease
19%
Patient Outcomes
19%
Emergency Department
19%
Patients with Diabetes Mellitus
18%
Strategy Trials
18%
Medicine and Dentistry
Cardiovascular System
93%
Cardiovascular Disease
68%
Atherosclerosis
64%
Percutaneous Coronary Intervention
58%
Revascularization
43%
Coronary Artery Disease
41%
Cardiovascular Risk
38%
Clinical Trial
36%
Atrial Fibrillation
30%
Diabetes
29%
Apoplexy
28%
Health Promotion
27%
Antithrombotic
25%
Myocardial Infarction
25%
Bleeding
23%
Acute Coronary Syndrome
22%
Diabetes Mellitus
22%
Polyethylene Terephthalate
21%
Ischemic Heart Disease
19%
Emergency Department
19%
Positron Emission Tomography-Computed Tomography
18%
Lifestyle Intervention
18%
Secondary Prevention
18%
Patient with Diabetes
18%
Fluorodeoxyglucose F 18
18%
Bradycardia
18%
Positron Emission Tomography
16%
Blood Pressure
16%
Low and Middle Income Countries
15%
Triage
15%
Disease
15%
Health Care Cost
14%
Prevalence
13%
Reproducibility
13%
Alimentation
13%
Carotid Artery
12%
Coronary Artery Bypass Graft
12%
Drug-Eluting Stent
12%
Hazard Ratio
12%
Randomized Controlled Trial
12%
Chronic Kidney Disease
12%
Antiplatelet
12%
Lifespan
11%
Acute Heart Infarction
11%
Risk Stratification
11%
Maturity Onset Diabetes of the Young
11%
Diseases
10%
Biological Marker
10%
Troponin
10%
Thorax Pain
10%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Infarction
77%
Ticagrelor
63%
Acute Coronary Syndrome
55%
Cardiovascular Disease
54%
Bleeding
53%
Coronary Artery Disease
47%
Diabetes Mellitus
44%
Cerebrovascular Accident
40%
Placebo
37%
Non Insulin Dependent Diabetes Mellitus
33%
Clopidogrel
28%
Clinical Trial
27%
Atrial Fibrillation
27%
Atherosclerosis
22%
Low Density Lipoprotein Cholesterol
21%
Anticoagulant Agent
20%
Chronic Kidney Failure
19%
Ischemic Heart Disease
19%
All Cause Mortality
19%
Acute Heart Infarction
18%
Dapagliflozin
18%
Bivalirudin
18%
Prasugrel
18%
Disease
17%
Cardiovascular Risk
17%
Prevalence
15%
Pulmonary Hypertension
15%
Antiplatelet
15%
Combination Therapy
14%
Riociguat
14%
Congestive Heart Failure
14%
Randomized Controlled Trial
12%
Hyperglycemia
12%
Antithrombotic Therapy
11%
Fibrinogen Receptor
10%
Biological Marker
10%
High Density Lipoprotein Cholesterol
10%
Stent Thrombosis
9%
Rivaroxaban
9%
Minimal Residual Disease
9%
Anacetrapib
9%
Diabetic Cardiomyopathy
9%
Vascular Disease
9%
Chronic Thromboembolic Pulmonary Hypertension
9%
Insulin Resistance
9%
Cystatin C
9%
Metabolic Syndrome X
9%
Blood Clotting Factor 10a
9%
C Reactive Protein
9%
Monotherapy
9%